IPO Monitor
Subscribe Login Login About Us Contact Us Help
Latest IPO News (beta)

[ All Markets | U.S. | Canada | Europe | China ]


Chemicals distribution group Azelis considers 2018 IPO -sources

Belgium-based chemicals distribution group Azelis is considering a 2018 stock market listing as its private equity owner seeks to benefit from high sector valuations, sources close to the matter said. Buyout group Apax, which bought Azelis from 3i in early 2015, could seek a valuation of more than 1.3 billion euros through the possible IPO, they added.
[ Fidelity at 2017-12-11 10:29:47 ]


BRIEF-Blank Check Co, Mtech Acquisition Files For IPO Of Upto $50 Mln

Mtech Acquisition Corp. * BLANK CHECK COMPANY, MTECH ACQUISITION CORP FILES FOR IPO OF UPTO $50.0 MILLION - SEC FILING Source text : http://bit.ly/2yOxaey.
[ Fidelity at 2017-12-08 10:14:38 ]


5 things to know about biotech Denali Therapeutics and its $250 million IPO

Denali Therapeutics(DNLI) is taking on diseases that pharmaceutical companies have long tried-- and failed-- to treat. Buzzed-about new biotech Denali Therapeutics (DNLI) is taking on diseases that pharmaceutical companies have long tried-- and failed-- to treat. But because of the company's new approach, including a focus on genetic drivers of the diseases and developing medications that can cross from the bloodstream into the brain, Denali says it believes it can succeed where others...
[ Fidelity at 2017-12-08 08:26:23 ]


Biotech Denali Therapeutics shares surge more than 20% in trading debut

Shares of biotech Denali Therapeutics Inc. (DNLI) soared more than 20% in their trading debut Friday, after the company priced its initial public offering at the midpoint of its $17 to $19 price range. The company sold 13.9 million shares at $18 each to raise $250 million, giving it a valuation of $1.7 billion, according to Renaissance Capital, a manager of IPO-focused ETFs like the Renaissance IPO ETF. Goldman Sachs, Morgan Stanley and J.P.
[ Fidelity at 2017-12-08 08:21:37 ]


BRIEF-Luther Burbank Shares Debut 9.3 Pct Above IPO Price

* LUTHER BURBANK SHARES OPEN AT $11.75 IN DEBUT ON THE NASDAQ VERSUS IPO PRICE OF $10.75/SHARE Further company coverage:
[ Fidelity at 2017-12-08 07:59:00 ]


BRIEF-Golden Metropolis International Files For U.S. IPO Of Up To $10.0 Mln

Golden Metropolis International Ltd. * GOLDEN METROPOLIS INTERNATIONAL LTD FILES FOR U.S. IPO OF UP TO $10.0 MILLION - SEC FILING. * GOLDEN METROPOLIS INTERNATIONAL LTD SAYS PLANS TO LIST ORDINARY SHARES ON NASDAQ CAPITAL MARKET UNDER SYMBOL “WALL”. * GOLDEN METROPOLIS INTERNATIONAL LTD SAYS BOUSTEAD SECURITIES IS THE UNDERWRITER TO THE IPO.
[ Fidelity at 2017-12-08 07:56:52 ]


Neo Completes Initial Public Offering


[ GlobeNewswire at 2017-12-08 06:00:00 ]


GigCapital prices IPO at $10 a unit

Blank-check company GigCapital Inc. (GIG/U) said it has priced its initial public offering at $10 a share. A blank-check company is one that has no assets, but plans to use the proceeds of the deal to acquire them. The company sold 12.5 million units to raise $125 million.
[ Fidelity at 2017-12-08 05:43:09 ]


BRIEF-Gigcapital, Inc. Announces Pricing Of $125,000,000 Initial Public Offering

Gigcapital Inc: * GIGCAPITAL, INC. ANNOUNCES PRICING OF $125,000,000 INITIAL PUBLIC OFFERING. * GIGCAPITAL INC - PRICED ITS INITIAL PUBLIC OFFERING OF 12.5 MILLION UNITS AT A PRICE OF $10.00 PER UNIT Source text for Eikon: Further company coverage:
[ Fidelity at 2017-12-08 05:42:09 ]


Denali Therapeutics prices IPO at $18 a share, midpoint of price range

Biotech Denali Biotherapeutics Inc. priced its initial public offering at $18 a share, the midpoint of its $17 to $19 price range. The company sold 13.9 million shares to raise $250 million, giving it a valuation of $1.7 billion, according to Renaissance Capital, a manager of IPO-focused ETFs like the Renaissance IPO ETF. Goldman Sachs, Morgan Stanley and J.P.
[ Fidelity at 2017-12-08 05:37:47 ]


5 things to know about biotech Denali Therapeutics and its $250 million IPO

Denali Therapeutics(DNLI) is taking on diseases that pharmaceutical companies have long tried-- and failed-- to treat. Buzzed-about new biotech Denali Therapeutics (DNLI) is taking on diseases that pharmaceutical companies have long tried-- and failed-- to treat. But because of the company's new approach, including a focus on genetic drivers of the diseases and developing medications that can cross from the bloodstream into the brain, Denali says it believes it can succeed where others...
[ Fidelity at 2017-12-08 04:01:23 ]


BRIEF-Luther Burbank Corporation Announces Pricing Of Initial Public Offering

Luther Burbank Corp: * ORATION ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING. * SAYS INITIAL PUBLIC OFFERING OF 12.2 MILLION COMMON SHARES PRICED AT $10.75PER SHARE. * ORATION ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING Source text for Eikon: Further company coverage:
[ Fidelity at 2017-12-07 20:00:58 ]


BRIEF-Denali Therapeutics Says Initial Public Offering Of 13.9 Mln Common Shares Priced At $18 per Share

Denali Therapeutics Inc: * DENALI THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING. * SAYS INITIAL PUBLIC OFFERING OF 13.9 MILLION COMMON SHARES PRICED AT $18.00PER SHARE Source text for Eikon: Further company coverage:
[ Fidelity at 2017-12-07 16:09:32 ]


Denali Therapeutics Announces Pricing of Initial Public Offering


[ GlobeNewswire at 2017-12-07 16:08:00 ]


5 things to know about biotech Denali Therapeutics and its $250 million IPO

Denali Therapeutics is taking on diseases that pharmaceutical companies have long tried-- and failed-- to treat. Buzzed-about new biotech Denali Therapeutics is taking on diseases that pharmaceutical companies have long tried-- and failed-- to treat. But because of the company's new approach, including a focus on genetic drivers of the diseases and developing medications that can cross from the bloodstream into the brain, Denali says it believes it can succeed where others...
[ Fidelity at 2017-12-07 08:29:30 ]


Denali Therapeutics upsizes IPO, to raise $250 million at midpoint of price range

Biotech Denali Therapeutics Inc. increased the size of its planned initial public offering Thursday, saying it now intends to say 13.9 million shares priced at $17 to $19 a pop. The company would raise $250 million at the midpoint of that range, up from a previous plan to raise $150 million. The company is planning to list on Nasdaq under the ticker symbol "DNLI".
[ Fidelity at 2017-12-07 08:26:09 ]


BRIEF-Quanterix Corp Shares Debut 8.3 pct Above IPO Price

* QUANTERIX CORP SHARES OPEN AT $16.25 IN DEBUT ON THE NASDAQ VERSUS IPO PRICE OF $15.00 PER SHARE Further company coverage:
[ Fidelity at 2017-12-07 07:47:59 ]


BRIEF-Curo Group Holdings Corp Shares Debut 5.7 pct Above IPO Price

* CURO GROUP HOLDINGS CORP SHARES OPEN AT $14.80 IN DEBUT ON NYSE VERSUS IPO PRICE OF $14.00 PER SHARE Further company coverage:
[ Fidelity at 2017-12-07 06:59:57 ]


Online lender Curo's stock jumps 3.6% in trading debut

Online lender Curo Group Holdings Corp.' s shares were up 3.6% in their trading debut Thursday, after the company priced its initial public offering at $14 a share. The company sold 6.7 million shares to raise $93.8 million. Proceeds will be used to pay down debt.
[ Fidelity at 2017-12-07 06:57:43 ]


BRIEF-CURO Announces Pricing Of Initial Public Offering

Curo Group Holdings Corp(CURO): * CURO ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING. * SAYS INITIAL PUBLIC OFFERING OF 6.67 MILLION COMMON SHARES PRICED AT $14.00PER SHARE Source text for Eikon: Further company coverage:
[ Fidelity at 2017-12-07 05:15:30 ]


More IPO News >>    

[ Contact Us | About Us | Site Map ]

Copyright (c) 1998-2017 IPO Monitor. All rights reserved